HOUSTON, April 8 /PRNewswire/ -- LaserGen, Inc., a DNA sequencing technology company, announced a definitive agreement in which SeqWright Inc. will make an equity investment in the company. Prompting its decision was LaserGen's recently revealed plans to commercialize its novel reversible terminator chemistry, Lightning Terminators(TM), for next-generation sequencing applications. The company anticipates bringing its chemistry as reagent kits to the market as early as 2010, by forming strategic partnerships with existing next-generation instrument manufacturers. SeqWright's investment and next-generation sequencing expertise are expected to facilitate LaserGen's effort in achieving that goal. Financial terms of the transaction were not disclosed.
The superior kinetics and natural DNA restoration of Lightning Terminators(TM) inform the promise of increased speed, throughput, and read-length, while lowering cost. These benefits are achieved through LaserGen's nucleotide chemistry by attaching a special terminating group directly to the base, freeing up the critical 3'-hydroxyl group. These Lightning Terminators(TM) exhibit excellent enzymatic properties with commercially available DNA polymerases. In kinetic terms, Lightning Terminators(TM) are more efficient than natural nucleotides, a measure of how fast they are added by and how well they bind to DNA polymerase. Simply stated, Lightning Terminators(TM) are better than nature. All reversible terminators required a cleavage step to remove the terminating and fluorescent dye groups. Upon cleavage, however, Lightning Terminators(TM) restore the incorporated nucleotide back to its natural state. This distinguishes the LaserGen chemistry from other reversible terminators, which leave accumulating molecular scars as the DNA strand propagates.
The decision to invest in LaserGen represents SeqWright's ongoing initiative to support
|SOURCE SeqWright Inc.; LaserGen, Inc.|
Copyright©2009 PR Newswire.
All rights reserved